Telix Pharmaceuticals (ASX:TLX) has announced that preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma support the patient benefit seen in the IPAX-1 study. …
Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate
April 16, 2025 Australian Biotech
Latest Video
New Stories
-
Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate
April 16, 2025 - - Australian Biotech -
Prescient's PTX-100 receives US FDA Fast Track Designation
April 16, 2025 - - Australian Biotech -
Australian research finds turning off protein may help prevent liver cancer
April 16, 2025 - - Australian Biotech -
UQ tests vaccine response in ‘moonshot’ challenge
April 16, 2025 - - Australian Biotech -
Cartherics announces board changes, including a new chair
April 16, 2025 - - Australian Biotech -
UCB welcomes new TGA registration for monoclonal antibody
April 16, 2025 - - Latest News -
Investors appear comfortable as Trump administration says pharma tariffs coming
April 16, 2025 - - Latest News